X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-04-02 | VYGR | Ferguson Toby | Chief Medical Officer | S - Sale | $3.43 | -10,086 | 157,914 | -6% | -$34,595 | ||||||
2025-04-02 | VYGR | Sandrock Alfred | Pres, CEO | S - Sale | $3.43 | -10,885 | 430,931 | -2% | -$37,336 | ||||||
| D | 2025-02-20 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale+OE | $4.26 | -3,305 | 123,718 | -3% | -$14,079 | |||||
| D | 2025-02-20 | VYGR | Sandrock Alfred | Pres, CEO | S - Sale+OE | $4.24 | -11,702 | 441,816 | -3% | -$49,616 | |||||
| D | 2025-02-20 | VYGR | Swartz Robin | COO, CBO | S - Sale+OE | $4.25 | -3,894 | 169,647 | -2% | -$16,550 | |||||
2025-02-11 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale | $4.45 | -5,413 | 81,023 | -6% | -$24,088 | ||||||
2025-02-11 | VYGR | Swartz Robin | COO, CBO | S - Sale | $4.45 | -6,950 | 102,291 | -6% | -$30,928 | ||||||
2025-02-11 | VYGR | Sandrock Alfred | Pres, CEO | S - Sale | $4.45 | -16,644 | 308,518 | -5% | -$74,066 | ||||||
2025-02-11 | VYGR | Fahey Sandell Jacquelyn | GC | S - Sale | $4.45 | -4,358 | 81,643 | -5% | -$19,393 | ||||||
2025-01-14 | VYGR | Swartz Robin | COO, CBO | S - Sale | $5.09 | -3,087 | 109,241 | -3% | -$15,713 | ||||||
2025-01-14 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale | $5.13 | -1,191 | 86,436 | -1% | -$6,110 | ||||||
2024-12-23 | VYGR | Swartz Robin | COO, CBO | S - Sale | $5.65 | -6,500 | 112,328 | -5% | -$36,725 | ||||||
2024-10-02 | VYGR | Fahey Sandell Jacquelyn | GC | S - Sale | $5.82 | -5,999 | 86,001 | -7% | -$34,914 | ||||||
2024-04-02 | VYGR | Swartz Robin | COO | S - Sale | $9.88 | -1,357 | 117,004 | -1% | -$13,407 | ||||||
2024-04-02 | VYGR | Sandrock Alfred | Pres, CEO | S - Sale | $9.86 | -12,115 | 322,839 | -4% | -$119,454 | ||||||
2024-02-21 | VYGR | Swartz Robin | COO | S - Sale | $7.45 | -3,966 | 118,361 | -3% | -$29,547 | ||||||
2024-02-21 | VYGR | Sandrock Alfred | Pres, CEO | S - Sale | $7.46 | -13,033 | 334,954 | -4% | -$97,226 | ||||||
2024-02-21 | VYGR | Pfreundschuh Peter P. | CFO | S - Sale | $7.46 | -3,764 | 175,669 | -2% | -$28,079 | ||||||
| M | 2024-02-20 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale | $7.50 | -3,967 | 87,627 | -4% | -$29,760 | |||||
2024-01-17 | VYGR | Swartz Robin | COO | S - Sale | $7.15 | -2,543 | 72,327 | -3% | -$18,182 | ||||||
2024-01-17 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale | $7.18 | -1,266 | 53,094 | -2% | -$9,090 | ||||||
2023-10-03 | VYGR | Pfreundschuh Peter P. | CFO | S - Sale | $6.99 | -13,567 | 149,433 | -8% | -$94,833 | ||||||
| D | 2023-09-15 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale+OE | $8.16 | -10,500 | 54,360 | -16% | -$85,680 | |||||
2023-07-06 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale | $10.80 | -5,500 | 59,860 | -8% | -$59,400 | ||||||
| D | 2023-06-30 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale+OE | $11.41 | -5,000 | 65,360 | -7% | -$57,050 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |